Biotech Values

[DewDiligence]

Viread got a 6-month pediatric extension from the FDA, which means GILD’s US patent protection on Viread, Truvada, and Atripla now expires on 1/25/18. The Orange Book is already updated accordingly:

http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021356&Product_No=001&table1=OB_Rx

http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021752&Product_No=001&table1=OB_Rx

http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021937&Product_No=001&table1=OB_Rx